A new application for technology used in medicine has been discovered thanks to the collaboration between RIS (Reparto Investigazioni Scientifiche - Crime Scene Investigation Department) of the Carabinieri (Italian police) of Rome and Menarini. Destined to change the world of forensic science, this new technology application has even been published in the journal "Forensic Science International."

Milan (Italy) 10 September 2017: Perhaps due to the difficulty of admitting their illness, or perhaps because of a mere difference in terminology and language, 9 out of 10 patients with chronic obstructive pulmonary disease (COPD) do not inform their doctor of their real condition. A study1 published in the International Journal of COPD sheds light on the lack of effective, bi-directional communication which often affects the state of health of patients. The study will be present at the 2017 European Respiratory Society (ERS) Congress, to be held from 9 to 13 September in Milan.

Krakow/Berlin, March 28, 2017 – Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients.

The Menarini Group has consolidated its presence in Latin America with new affiliates in Colombia and Peru. Both countries have emerging economies which offer the company opportunities for market expansion with its high-quality pharmaceuticals. Two new affiliates have just been opened in Bogotá and Lima, strengthening the connection between two continents and creating a springboard for other areas of expansion in Latin America.

NEW HAVEN, Conn. and FLORENCE, Italy, March 1, 2017 – Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced the signing of a development and commercialization agreement.

Florence, 18 January 2017: 25% is an impressive growth rate for Ibrahim Etem Menarini, the Turkish company of the Menarini Group, ranking 6th among the top pharma companies for the number of packages sold in a large and diverse market with a turnover of 410 million Turkish liras (125 million euros) and 800 employees.